|Articles|November 15, 2016
Physicians Want Strong FDA Biosimilar Naming
The Biologics Prescribers Collaborative has released findings from a physician’s survey about the FDA’s proposed biosimilar naming guidelines.
Advertisement
The Biologics Prescribers Collaborative has released findings from a physician’s survey about the FDA’s proposed biosimilar naming guidelines. According to the survey, 80 percent of physicians prefer a meaningful four-letter suffix that notes the biosimilar manufacturer’s name as opposed to a random four-letter suffix.
Read the full release here
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- eClinical Technology: Misconceptions, Challenges, and Opportunities
September 9th 2025
- How Sponsors Can Modernize Tools to Support Physicians
September 9th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer
2
Investigational OX40-Targetting T-Cell Therapy Shows Durable Efficacy Treating Atopic Dermatitis in Phase III Trial
3
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
4
Phase III EMPOWER-Lung 3 Trial Confirms Five-Year Survival Benefit With Libtayo Plus Chemotherapy in NSCLC
5